{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=3&sponsor=Neurocrine+Biosciences",
    "query": {
      "sponsor": "Neurocrine Biosciences",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 75,
    "total_pages": 8,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=4&sponsor=Neurocrine+Biosciences&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=2&sponsor=Neurocrine+Biosciences&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T16:03:05.498Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01403038",
      "title": "An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Folliculogenesis"
      ],
      "interventions": [
        {
          "name": "elagolix",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie (prior sponsor, Abbott)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 216,
      "start_date": "2011-06",
      "completion_date": "2012-11",
      "has_results": false,
      "last_update_posted_date": "2013-01-08",
      "last_synced_at": "2026-10-17T16:03:05.498Z",
      "location_count": 20,
      "location_summary": "Colorado Springs, Colorado • Denver, Colorado • Lonetree, Colorado + 14 more",
      "locations": [
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Lonetree",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01403038"
    },
    {
      "nct_id": "NCT03525886",
      "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal Hyperplasia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "CAH - Congenital Adrenal Hyperplasia"
      ],
      "interventions": [
        {
          "name": "NBI-74788",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurocrine Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 18,
      "start_date": "2018-04-10",
      "completion_date": "2020-04-07",
      "has_results": true,
      "last_update_posted_date": "2022-05-03",
      "last_synced_at": "2026-10-17T16:03:05.498Z",
      "location_count": 6,
      "location_summary": "Aurora, Colorado • Indianapolis, Indiana • Ann Arbor, Michigan + 3 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03525886"
    },
    {
      "nct_id": "NCT05654870",
      "title": "Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Valbenazine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurocrine Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2023-01-05",
      "completion_date": "2023-11-08",
      "has_results": false,
      "last_update_posted_date": "2024-11-12",
      "last_synced_at": "2026-10-17T16:03:05.498Z",
      "location_count": 3,
      "location_summary": "San Jose, California • Coral Gables, Florida • Atlanta, Georgia",
      "locations": [
        {
          "city": "San Jose",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05654870"
    },
    {
      "nct_id": "NCT03062033",
      "title": "Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Tardive Dyskinesia"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Neurocrine Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2017-04-04",
      "completion_date": "2018-08",
      "has_results": false,
      "last_update_posted_date": "2017-11-22",
      "last_synced_at": "2026-10-17T16:03:05.498Z",
      "location_count": 34,
      "location_summary": "Little Rock, Arkansas • Anaheim, California • Long Beach, California + 29 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Gatos",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03062033"
    },
    {
      "nct_id": "NCT06060444",
      "title": "Evaluating a Telemedicine Neurological Consult Program for Drug-Induced Movement Disorders Using the RE-AIM Framework",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Drug-Induced Movement Disorder"
      ],
      "interventions": [
        {
          "name": "Telemedicine Consult",
          "type": "OTHER"
        },
        {
          "name": "In-person Consult",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Vermont",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2022-04-26",
      "completion_date": "2024-10-31",
      "has_results": false,
      "last_update_posted_date": "2024-11-05",
      "last_synced_at": "2026-10-17T16:03:05.498Z",
      "location_count": 1,
      "location_summary": "Burlington, Vermont",
      "locations": [
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06060444"
    },
    {
      "nct_id": "NCT07536269",
      "title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Congenital Adrenal Hyperplasia"
      ],
      "interventions": [
        {
          "name": "Crinecerfont",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurocrine Switzerland GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": "47 Months",
        "sex": "ALL",
        "summary": "3 Months to 47 Months"
      },
      "enrollment_count": 20,
      "start_date": "2026-07-01",
      "completion_date": "2028-03",
      "has_results": false,
      "last_update_posted_date": "2026-09-16",
      "last_synced_at": "2026-10-17T16:03:05.498Z",
      "location_count": 11,
      "location_summary": "San Francisco, California • Aurora, Colorado • Hartford, Connecticut + 8 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07536269"
    },
    {
      "nct_id": "NCT04787965",
      "title": "Opicapone Treatment Initiation Open-Label Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "Opicapone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurocrine Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 239,
      "start_date": "2021-03-01",
      "completion_date": "2022-08-04",
      "has_results": false,
      "last_update_posted_date": "2022-11-28",
      "last_synced_at": "2026-10-17T16:03:05.498Z",
      "location_count": 6,
      "location_summary": "Los Gatos, California • Memphis, Tennessee • Christiansburg, Virginia + 3 more",
      "locations": [
        {
          "city": "Los Gatos",
          "state": "California"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Christiansburg",
          "state": "Virginia"
        },
        {
          "city": "Norfolk",
          "state": "Virginia"
        },
        {
          "city": "Auburn",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04787965"
    },
    {
      "nct_id": "NCT07105111",
      "title": "A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder",
        "Bipolar Disorder",
        "Major Depressive Disorder",
        "Tardive Dyskinesia"
      ],
      "interventions": [
        {
          "name": "Valbenazine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurocrine Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2025-08-29",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-10-17T16:03:05.498Z",
      "location_count": 19,
      "location_summary": "Bryant, Arkansas • Chino, California • Fresno, California + 16 more",
      "locations": [
        {
          "city": "Bryant",
          "state": "Arkansas"
        },
        {
          "city": "Chino",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07105111"
    },
    {
      "nct_id": "NCT05053321",
      "title": "Reduction of Demoralization in Patients With Tardive Dyskinesia After Treatment With Valbenazine",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tardive Dyskinesia"
      ],
      "interventions": [
        {
          "name": "Valbenazine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "26 Years",
        "maximum_age": "84 Years",
        "sex": "ALL",
        "summary": "26 Years to 84 Years"
      },
      "enrollment_count": 0,
      "start_date": "2024-10-18",
      "completion_date": "2025-10-18",
      "has_results": false,
      "last_update_posted_date": "2025-07-11",
      "last_synced_at": "2026-10-17T16:03:05.498Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05053321"
    },
    {
      "nct_id": "NCT04873869",
      "title": "Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "SCN8A Developmental and Epileptic Encephalopathy Syndrome"
      ],
      "interventions": [
        {
          "name": "NBI-921352",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurocrine Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "2 Years to 21 Years"
      },
      "enrollment_count": 8,
      "start_date": "2022-01-31",
      "completion_date": "2023-03-17",
      "has_results": true,
      "last_update_posted_date": "2025-10-16",
      "last_synced_at": "2026-10-17T16:03:05.498Z",
      "location_count": 4,
      "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Rochester, New York + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04873869"
    }
  ]
}